Millendo expands orphan endocrinology pipeline with acquisition

Millendo Therapeutics, a University of Michigan, USA, start-up company, says it has acquired French drug developer Alizé Pharma SAS in a stock-based transaction, the value of which has not been disclosed.

“The acquisition of Alizé Pharma SAS transforms Millendo into an innovative endocrinology company with two first-in-class, late-stage clinical assets and a presence in both the United States and Europe. With livoletide, we have acquired a promising asset that has demonstrated encouraging efficacy and tolerability in a Phase II clinical trial in PWS [Prader-Willi Syndrome],” said Julia Owens, president and chief executive of Millendo Therapeutics.